U.S. Magistrate Judge Joel Schneider of the U.S. District Court for the District of New Jersey. Photo by Carmen Natale
A federal judge overseeing multidistrict litigation over the drug valsartan has denied a request for discovery of litigation funding arrangements involving the plaintiffs.
No binding U.S. Court of Appeals for the Third Circuit precedent addresses whether a plaintiff’s litigation funding is a proper subject of discovery, U.S. Magistrate Judge Joel Schneider said in a ruling Wednesday. The plaintiff’s argument—that litigation funding is irrelevant to the claims and defenses in the case—won out over the defendants’ “parade of horribles” that could arise from litigation funding agreements, Schneider said.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
